Information about actively enrolling, ongoing, and completed clinical trials of cancer prevention, early detection, and supportive care, including phase I, II, and III agent and action trials and clinical trials management.
At the very first mention of my cancer diagnosis, all I could think of was “How do I beat this…what’s my best course of action?” A clinical trial was the answer. I had never heard of Multiple Myeloma, so I wasn’t real confident that there would be a trial for me to join. I was so relieved when there was. How could one not benefit from constant monitoring and undergoing extra testing? I have done extremely well and have had no setbacks. I don’t know if I would be in the same spot if it weren’t for the trial. I am so thankful for the doctors and researchers that work tirelessly toward a cure.
Type(s) of Trial: Treatment
Trial Link(s): Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Monograph on Engaging Older Adults in Clinical Trials
A JNCI monograph on Engaging Older Adults in Cancer Clinical Trials Conducted in the National Cancer Institute Clinical Trials Network. The articles, developed through working groups formed for an NCI workshop held in April 2021 to address this issue, provide recommendations and new and innovative solutions to common barriers to accrual.
Researchers Search the Genome for Clues to Early Age Onset Cancers in Racial/Ethnic Minorities
While researchers have identified some of the genetic changes that lead to cancer development, a key knowledge gap remains: finding the genetic changes that drive the development of cancers that arise at an earlier age than average (early onset) in racially and ethnically diverse populations.
New Onset Diabetes Cohort Sought to Unravel Complexities of Pancreatic Cancer Development
The National Cancer Institute is leading a project to create a cohort of people who are newly diagnosed with diabetes in the hopes that this group, who are at increased risk of developing pancreatic cancer, provide the clues in their blood and tissues to unravel some of the unknowns about this highly fatal cancer. The New Onset Diabetes Study (NOD) will include 10,000 people ages 50 to 85 across the United States.